4.07
                                            Schlusskurs vom Vortag:
              $4.06
            Offen:
              $4.05
            24-Stunden-Volumen:
                5,866
            Relative Volume:
              0.13
            Marktkapitalisierung:
                $1.45B
            Einnahmen:
              $842.96M
            Nettoeinkommen (Verlust:
              $-185.63M
            KGV:
              -7.7391
            EPS:
                -0.5259
            Netto-Cashflow:
                $-228.52M
            1W Leistung:
              -0.73%
            1M Leistung:
              +12.12%
            6M Leistung:
                -3.10%
            1J Leistung:
              +5.17%
            Evotec Se Adr Stock (EVO) Company Profile
Vergleichen Sie EVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV | 
|---|---|---|---|---|---|---|
|   
                          
                                EVO
                            
                             Evotec Se Adr | 4.08 | 1.44B | 842.96M | -185.63M | -228.52M | -0.5259 | 
|   
                          
                                ZTS
                            
                             Zoetis Inc | 143.18 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 | 
|   
                          
                                TAK
                            
                             Takeda Pharmaceutical Co Adr | 13.46 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 | 
|   
                          
                                HLN
                            
                             Haleon Plc Adr | 9.205 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 | 
|   
                          
                                TEVA
                            
                             Teva Pharmaceutical Industries Ltd Adr | 20.14 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 | 
|   
                          
                                UTHR
                            
                             United Therapeutics Corp | 449.15 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 | 
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung | 
|---|---|---|---|
| 2025-04-24 | Hochstufung | Deutsche Bank | Sell → Hold | 
| 2024-10-07 | Herabstufung | Jefferies | Buy → Hold | 
| 2024-08-08 | Herabstufung | Deutsche Bank | Hold → Sell | 
| 2024-07-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight | 
| 2024-07-11 | Herabstufung | Deutsche Bank | Buy → Hold | 
| 2024-04-12 | Hochstufung | Deutsche Bank | Hold → Buy | 
| 2024-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform | 
| 2023-06-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight | 
| 2023-06-16 | Herabstufung | BofA Securities | Buy → Neutral | 
| 2023-06-08 | Hochstufung | Citigroup | Neutral → Buy | 
| 2023-04-04 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight | 
| 2022-12-09 | Eingeleitet | H.C. Wainwright | Buy | 
| 2022-11-16 | Herabstufung | Deutsche Bank | Buy → Hold | 
| 2022-08-10 | Herabstufung | Morgan Stanley | Overweight → Underweight | 
| 2022-03-02 | Fortgesetzt | Cowen | Outperform | 
| 2022-01-07 | Fortgesetzt | Citigroup | Neutral | 
                    Alle ansehen
                     
                  
                Evotec Se Adr Aktie (EVO) Neueste Nachrichten
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner - Benzinga
ETFs Investing in Evotec SE Sponsored ADR Stocks - TradingView
Evotec (NASDAQ:EVO) versus CASI Pharmaceuticals (NASDAQ:CASI) Critical Survey - Defense World
Evotec Ag’s Earnings Call: Mixed Sentiments and Strategic Moves - MSN
Stock Information - Evotec
Annual General Meeting - Evotec
Evotec SE ADR earnings missed by $0.07, revenue fell short of estimates - Investing.com South Africa
Evotec AG Reports Mixed H1 2025 Performance - TipRanks
Ørsted announces plan for a rights issue with support from the Danish State as majority shareholder and gross proceeds of DKK 60 billion11.08.25NewsARIVA.DE - rova
Evotec shares drop sharply after lowering 2025 revenue forecast - MSN
Evotec and Sandoz plan potential sale of Toulouse biologics site By Investing.com - Investing.com South Africa
Evotec and Sandoz plan potential sale of Toulouse biologics site - Investing.com
Evotec SE (EVO) Stock Forecasts - Yahoo Finance
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union - Ariva
SAP Quarterly Statement Q2 202522.07.25News - Ariva
Evotec stock tumbles after slashing 2025 revenue guidance - Investing.com Australia
Evotec stock tumbles after slashing 2025 revenue guidance By Investing.com - Investing.com Canada
8 New 4-Star Stocks - Morningstar
Evotec SE ADR (EVO) Strikes $4.73: The Risk Seems Worthwhile At This Price - Stocksregister
Evotec SE ADR earnings missed by $0.03, revenue fell short of estimates - Investing.com Nigeria
Evotec Ag Earnings Call: Mixed Sentiment Amid Growth - TipRanks
Evotec AG Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Evotec shares surge 51% following InvestingPro’s undervalued signal By Investing.com - Investing.com India
Evotec SE ADR earnings beat by $0.08, revenue topped estimates - Investing.com
Evotec SE Reports Strong Q4 2024 and New Strategy - TipRanks
Evotec Ag’s Earnings Call: Growth Amid Challenges - TipRanks
Bayer, BioNxt Solutions, Evotec – falscher Zoll Alarm bei Pharma und Biotech! Welche Aktien lohnen sich? - kapitalerhoehungen.de
Evotec: Some Recovery Has Come, But Much More Is Expected - Seeking Alpha
Markets Brief: Are Bank Stocks Expensive? - Morningstar
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - Baystreet.ca
Investor Relations - Evotec
Earnings call: Evotec SE revises 2024 outlook amid market challenges - Investing.com
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar Canada
Healthcare Sector - Morningstar
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com India
Earnings call: Evotec SE meets 2023 guidance, appoints new CEO - Investing.com
Evotec: Still A Speculative Buy After A Significant Decline (NASDAQ:EVO) - Seeking Alpha
Evotec and Variant Bio partner to develop fibrosis treatments - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Finanzdaten der Evotec Se Adr-Aktie (EVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
        In Yahoo öffnen
        |
        In Google öffnen
            |
            In Finviz öffnen
        |
        In MarketWatch öffnen
            |
            Öffnen Sie in EDGAR    
        |
        Offen in Reuters
    
    
                Kapitalisierung:
                 
                  | 
                Volumen (24h):
                 
            
         
                     
                             Holen Sie sich die Stockscreener-App
                    Holen Sie sich die Stockscreener-App